John Nelson, MD
Pulmonary Disease · Overland Park, KSNPI 1417040890
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $888 of the $1,165 with a category attached, or 76.2%. 15 manufacturers reported payments, led by Harmony Biosciences LLC at 30.6% of the total. 2025 is the largest year on record at $552, 5.2 times the $107 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in KS, where the typical reported total is $1,991.
Across 37 payments — averaging $31.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$357
- GSK$148
- Abiomed$146
- Sanofi$124
- Jazz Pharmaceuticals Inc.$113
- Insmed, Inc.$74
- plus $203 from 9 others
What the payments were for
- Food & beverage$88876%
- Education$27724%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 9 | $357 |
| GSK | 6 | $148 |
| Abiomed | 1 | $146 |
| Sanofi | 2 | $124 |
| Jazz Pharmaceuticals Inc. | 2 | $113 |
| Insmed, Inc. | 4 | $74 |
| Grifols USA, LLC | 2 | $50 |
| Inogen, Inc. | 4 | $28 |
| Resmed Corp | 1 | $24 |
| Amgen | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Viatris Specialty LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,165 in reported general payments places this provider in the 40th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 12 | $148,047 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $100,584 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 106 | $58,846 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $35,823 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $30,840 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 70 | $12,204 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $10,731 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $8,457 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $8,357 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,195 |
| Spiriva HandihalerTiotropium Bromide | 12 | $5,843 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $5,614 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 219 | $5,322 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,492 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $4,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $148 | $197,955297 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Striverdi Respimat | $15 | $46,02181 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $19 | $22,43744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Overland Park
- Brietta ForbesOverland Park$10K
- Mitchell TenerOverland Park$6K
- Jason FieserOverland Park$6K
- James KaplanOverland Park$4K
- Daniel BalmacedaOverland Park$3K
- Trenton NauserOverland Park$1K
- Christine CookOverland Park$1K
- Scott EveloffOverland Park$903
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.